P579: SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF AZD5991 IN RELAPSED/ REFRACTORY HEMATOLOGIC MALIGNANCIES: A PHASE 1 FIRST-IN-HUMAN STUDY

• Pinkal Desai,
• Sagar Lonial,
• Amanda Cashen,
• Manali Kamdar,
• James S. Blachly,
• Ian W. Flinn,
• Susan O’brien,
• Jacqueline Garcia,
• Neha Korde,
• Javid Moslehi,
• Margaret Wey,
• Patricia Cheung,
• Shringi Sharma,
• Damilola Olabode,
• Hong Chen,
• Firasath Ali Syed,
• Mary Liu,
• Jamal Saeh,
• Raoul Tibes,
• Marcio Andrade,
• Tapan Kadia

Affiliations

Pinkal Desai

1 Weill Cornell Medical College, New York, United States

Sagar Lonial

2 Emory Winship Cancer Institute, Atlanta, United States

Amanda Cashen

3 Washington University Medical School, St Louis, United States

Manali Kamdar

4 University of Colorado Medicine, Denver, United States

James S. Blachly

5 Ohio State University Comprehensive Cancer Center, Columbus, United States

Ian W. Flinn

6 Tennessee Oncology, Nashbille, United States

Susan O’brien

7 UCI Health, Irvine, United States

Jacqueline Garcia

8 Dana-Farber Cancer Institute, Boston, United States

Neha Korde

9 Memorial Sloan Kettering Cancer Center, New York, United States

Javid Moslehi

10 University of California San Francisco, San Francisco, United States

Margaret Wey

11 AstraZeneca, Cambridge, United Kingdom

Patricia Cheung

11 AstraZeneca, Cambridge, United Kingdom

Shringi Sharma

12 AstraZeneca, South San Francisco, United States

Damilola Olabode

11 AstraZeneca, Cambridge, United Kingdom

Hong Chen

11 AstraZeneca, Cambridge, United Kingdom

Firasath Ali Syed

11 AstraZeneca, Cambridge, United Kingdom

Mary Liu

11 AstraZeneca, Cambridge, United Kingdom

Jamal Saeh

13 AstraZeneca, United Kingdom

Raoul Tibes

13 AstraZeneca, United Kingdom

Marcio Andrade

13 AstraZeneca, United Kingdom

Tapan Kadia

14 MD Anderson Cancer Center, Houston, United States